Purpose of this Study
The study team will collect medical record information from your hospitalization for pneumonia. You will also be asked to provide a urine (pee) sample for additional testing.
Who Can Participate?
Eligibility
Patients 65 years of age and older that are being evaluated at the hospital for pneumonia.
Age Range
65-110
Sex/Genders
Male (cisgender)
Female (cisgender)
Non-binary or gender fluid
Transgender male
Transgender female
Looking for Healthy Participants
No
What is Involved?
Description
The study wants to find out how well the CAPVAXIVE vaccine protects people from getting pneumonia caused by a bacteria called S Pneumoniae. The vaccine is already approved for adults, and the study is being done to see how well it works in real life, not just in earlier testing.
Locations
Duke University Hospital
Duke Regional Hospital
Duke Raleigh Hospital
Visit Timing
Weekdays
Compensation
Yes
Spanish Materials Available
Yes
Study Details
Full Title
DIA03: A Test-Negative Case-Control Study to Evaluate the
Effectiveness of V116, CAPVAXIVETM Against
Pneumococcal Pneumonia in Older Adults
Effectiveness of V116, CAPVAXIVETM Against
Pneumococcal Pneumonia in Older Adults
Principal Investigator
Emily
Ko
Protocol Number
PRO00119553
NCT ID
NA
Phase
N/A
Enrollment Status
Pending Open to Enrollment